Fund Tracker
NATCOPHARMNSEPharmaceuticals & Biotechnology

Natco Pharma Limited

₹839.30NSE close, 25 Sep 2026
Data as ofMF: Aug 2026 portfolios (monthly), 20 AMCsShares outstanding and close: NSE, 25 Sep 2026Delivery: NSE bhavcopy, 25 Sep 2026 · 30 days collectedDeals: NSE deal files, 25 Sep 2026 · collected since 25 Sep 2026SLBM: NSE, 25 Sep 2026 · 30 days collectedMTF: NSE, 24 Sep 2026 · 29 days collectedFlags: NSE, 25 Sep 2026FPI: Shareholding pattern as of 30 Jun 2026, filed 9 Jul 2026Pledge: Shareholding pattern as of 30 Jun 2026Insider: Disclosures filed 29 Jun 2026 to 26 Sep 2026 (collected since 3 May 2026)
MF holding, % of equity
0.74%▲ +0.09 pp
Aug 2026 · change vs Jul 2026 over 20 AMCs with both months, all schemes
FPI holding, % of equity
16.99%
as of 30 Jun 2026
Fund houses holding
5▲ +2
4 entered, 2 exited · Aug 2026 · index funds hidden
Promoter pledge
0.00%
as of 30 Jun 2026

What changed

5 tracked fund houses held NATCOPHARM in Aug 2026. Aditya Birla Sun Life Mutual Fund and 3 others entered; Samco Mutual Fund and 1 other exited.

All tracked schemes together held 13.26 lakh shares, 0.74% of equity, worth ₹112 cr at the end of Aug 2026.

Index and arbitrage funds held 0.46% of equity; they are left out of the fund-house counts.

MF houses

Aug 2026
5▲ +2 m/m
New4Added1Reduced0Exited2

Top buyer Aditya Birla Sun Life Mutual Fund, +0.07% of equity. Top seller Samco Mutual Fund, −0.04% of equity. Index and arbitrage funds hidden.

AMC portfolios, Aug 2026 · 20 AMCs trackedSource: AMC monthly portfolios (SEBI disclosure) 7 fund houses →

Named FPIs at 1% or more

as of 30 Jun 2026
16.99%

FPI category I + II, % of total shares · 1 named at 1% or more

FPIs named at 1% or more on 30 Jun 2026: BELGRAVE INVESTMENT FUND 2.31%.

Shareholding pattern as of 30 Jun 2026, filed 9 Jul 2026Source: NSE shareholding pattern filings (XBRL), quarterly

Insider and promoter

29 Jun 2026 to 26 Sep 2026
1▼ net −50,000 sh

disclosed transactions · equity bought 0 sh, sold 50,000 sh

Latest: DURGA DEVI NANNAPANENI (Promoter), Sell 50,000 Equity, 24 Aug 2026, Gift.

Disclosures filed 29 Jun 2026 to 26 Sep 2026 (collected since 3 May 2026)Source: NSE insider trading disclosures (SEBI PIT, XBRL)

Bulk and block deals

25 Sep 2026
No bulk or block deals in NATCOPHARM on 25 Sep 2026.
NSE deal files, 25 Sep 2026 · collected since 25 Sep 2026Source: NSE bulk.csv and block.csv, daily

Promoter pledge

as of 30 Jun 2026
0.00%

of promoter holding · 0.00% of total shares

Promoters had pledged 0 of their 8.85 cr shares on 30 Jun 2026.

Shareholding pattern as of 30 Jun 2026Source: NSE shareholding pattern filings (XBRL), quarterly

SLBM borrowing

25 Sep 2026
NSE listed no SLBS open position for NATCOPHARM on any of the 30 days collected, 14 Aug 2026 to 25 Sep 2026. No SLBM trades in NATCOPHARM on 25 Sep 2026.
NSE, 25 Sep 2026 · 30 days collectedSource: NSE SLBS open positions (slb_openpos) and SLBM bhavcopy (SLBM_BC), daily

MTF book

24 Sep 2026
18.29 lakh sh▼ −44,690 vs 23 Sep 2026

percentile 62 of 29 days collected · ₹180 cr financed

18.29 lakh shares, 1.02% of equity in the margin trading book at the end of 24 Sep 2026; that day sits at percentile 62 of 29 days collected.

NSE, 24 Sep 2026 · 29 days collectedSource: NSE margin trading disclosure (mrg_trading), daily

Delivery

25 Sep 2026
43.7%▼ −9.3 pp vs 20-day average

20-day average 53.0% · percentile 27 of 30 days collected

43.7% of the shares traded on 25 Sep 2026 were delivered, against a 20-day average of 53.0%; that day sits at percentile 27 of 30 days collected.

NSE bhavcopy, 25 Sep 2026 · 30 days collectedSource: NSE security-wise delivery file (sec_bhavdata_full), daily

Red flags

25 Sep 2026
No F&O

NATCOPHARM has no F&O contracts in NSE's combined open-interest file, so the F&O ban does not apply. NSE listed NATCOPHARM under no ASM or GSM stage on 25 Sep 2026. Pledge invocations are not collected yet.

NSE, 25 Sep 2026Source: NSE F&O ban file, combined OI (MWPL), surveillance indicators (REG1_IND), daily